Sanofi nabs EU approval for Toujeo; Shire defends ultralow tax rate;

@FiercePharma: Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Would any of you guys want to read a special report entitled "The secret first initials of biopharma CEOs and what they stand for"...? | Follow @CarlyHFierce

> Sanofi ($SNY) won European approval for its new basal insulin, Toujeo, intended as a follow-up to the blockbuster Lantus treatment that could face biosimilar competition this year. Release

> Dublin-based Shire ($SHPG) called its tax practices "mainstream" among multinational companies, in answer to shareholder questions about its $56 million 2014 tax bill, on $3.4 billion in profits. Report

> At least one analyst figures Teva's ($TEVA) Mylan ($MYL) bid would pay off even at a price of $100 per share, the figure Mylan quoted as a minimum starting point for negotiations. Report

> MannKind ($MNKD) is adding a 12-unit cartridge to its Afrezza line-up, a set of inhaled insulin products marketed by Sanofi. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Two U.S. hospitals to test startup's novel medical device malware detection software. Article | Follow @FierceMedDev

@VarunSaxena2: FDA bans manufacturing of Medtronic's infusion pump, citing violation of quality system regs. News | Follow @VarunSaxena2

@EmilyWFierce: Scanadu ropes in $35M for smartphone tricorder diagnostic device. More | Follow @EmilyWFierce

> Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system. Story

> 'Stealthy' Medina raises $6M in debt for cerebral aneurysm device after CE mark last fall. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Celgene bags a build-to-buy biotech in $485M cancer deal. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CEO Scangos commits $2.5B to a high stakes Alzheimer's gamble. More | Follow @JohnCFierce

> Resverlogix gets a $116M China drug development deal, stokes buyout buzz. More

> FDA bats down Merck's sugammadex in third rejection. Item

> Galapagos' arthritis drug shines in another PhIIb study as M&A rumors simmer. Article

Drug Delivery News

> Presage's multiple-cancer-drug injection device shows promising first-in-human results. Story

> Topical gel for migraine shows promise in trials, can penetrate transdermal barrier. Item

> 3M says its new intravenous port dressing will make drug delivery easier and fight off site infections. Report

> AbbVie's FDA-approved Duopa gel for Parkinson's skates through yearlong study. Story

> Generex announces second medical marijuana outlicensing deal for its drug delivery tech. Article

Pharma Manufacturing News

> Texas cancer center guilty of selling foreign-made Avastin. Item

> Wockhardt recalling all pre-ban products still in the U.S. More

> Mylan recalls injected cancer meds made for Pfizer. Story

> GSK licks Nicorette manufacturing problems; 'Minis' are back. Article

> Lilly's Elanco to unload former Novartis vax plant. News

Pharma Asia News

> Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies. Report

> India mulls adopting international standards on drug inspections, manufacturing. Story

> Cipla leans toward compromise in India court case over Onbrez from Novartis. More

> Japan's Panasonic joins Toshiba in rush to medical devices. Article

> Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. Item

And Finally... Suspected bird flu cases have popped up in 5 Iowa poultry farms, affecting some 6 million birds. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.